Logo image of NYKD.OL

NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Fundamental Analysis

OSL:NYKD - Euronext Oslo - NO0010714785 - Common Stock - Currency: NOK

1.796  -0.05 (-2.71%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NYKD. NYKD was compared to 65 industry peers in the Biotechnology industry. The financial health of NYKD is average, but there are quite some concerns on its profitability. NYKD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NYKD had negative earnings in the past year.
NYKD had a negative operating cash flow in the past year.
NYKD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NYKD reported negative operating cash flow in multiple years.
NYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFNYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

NYKD has a Return On Assets (-17.27%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -18.90%, NYKD is in the better half of the industry, outperforming 63.08% of the companies in the same industry.
Industry RankSector Rank
ROA -17.27%
ROE -18.9%
ROIC N/A
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
NYKD.OL Yearly ROA, ROE, ROICNYKD.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NYKD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NYKD.OL Yearly Profit, Operating, Gross MarginsNYKD.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

6

2. Health

2.1 Basic Checks

NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NYKD has about the same amount of shares outstanding.
NYKD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NYKD has an improved debt to assets ratio.
NYKD.OL Yearly Shares OutstandingNYKD.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
NYKD.OL Yearly Total Debt VS Total AssetsNYKD.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 2.89 indicates that NYKD is not a great score, but indicates only limited risk for bankruptcy at the moment.
NYKD's Altman-Z score of 2.89 is fine compared to the rest of the industry. NYKD outperforms 73.85% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that NYKD is not too dependend on debt financing.
The Debt to Equity ratio of NYKD (0.02) is better than 73.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 2.89
ROIC/WACCN/A
WACC8.61%
NYKD.OL Yearly LT Debt VS Equity VS FCFNYKD.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 16.92 indicates that NYKD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 16.92, NYKD belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.
A Quick Ratio of 16.92 indicates that NYKD has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 16.92, NYKD belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.92
Quick Ratio 16.92
NYKD.OL Yearly Current Assets VS Current LiabilitesNYKD.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.47% over the past year.
Looking at the last year, NYKD shows a very negative growth in Revenue. The Revenue has decreased by -25.95% in the last year.
Measured over the past years, NYKD shows a very negative growth in Revenue. The Revenue has been decreasing by -36.54% on average per year.
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.2%
Revenue 1Y (TTM)-25.95%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

NYKD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -66.63% yearly.
Based on estimates for the next years, NYKD will show a very strong growth in Revenue. The Revenue will grow by 184.95% on average per year.
EPS Next Y17.8%
EPS Next 2Y14.88%
EPS Next 3Y4.76%
EPS Next 5Y-66.63%
Revenue Next Year22.17%
Revenue Next 2Y-32.73%
Revenue Next 3Y-25.99%
Revenue Next 5Y184.95%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NYKD.OL Yearly Revenue VS EstimatesNYKD.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 1B 2B 3B 4B 5B
NYKD.OL Yearly EPS VS EstimatesNYKD.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NYKD. In the last year negative earnings were reported.
Also next year NYKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYKD.OL Price Earnings VS Forward Price EarningsNYKD.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYKD.OL Per share dataNYKD.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.88%
EPS Next 3Y4.76%

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 53.19%, NYKD is a good candidate for dividend investing.
NYKD's Dividend Yield is rather good when compared to the industry average which is at 11.85. NYKD pays more dividend than 100.00% of the companies in the same industry.
NYKD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.42.
Industry RankSector Rank
Dividend Yield 53.19%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y14.88%
EPS Next 3Y4.76%
NYKD.OL Yearly Income VS Free CF VS DividendNYKD.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

More info and screens

NYKODE THERAPEUTICS ASA

OSL:NYKD (7/4/2025, 11:18:27 AM)

1.796

-0.05 (-2.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-20 2025-08-20
Inst Owners16.22%
Inst Owner ChangeN/A
Ins Owners2.42%
Ins Owner ChangeN/A
Market Cap586.48M
Analysts80
Price Target5.2 (189.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 53.19%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.37%
PT rev (3m)-43.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)12.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)17.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.41
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.24
BVpS4.13
TBVpS4.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.27%
ROE -18.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.05%
Cap/Sales 1.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.92
Quick Ratio 16.92
Altman-Z 2.89
F-Score4
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)80.08%
Cap/Depr(5y)78.32%
Cap/Sales(3y)17.63%
Cap/Sales(5y)11.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.2%
EPS Next Y17.8%
EPS Next 2Y14.88%
EPS Next 3Y4.76%
EPS Next 5Y-66.63%
Revenue 1Y (TTM)-25.95%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year22.17%
Revenue Next 2Y-32.73%
Revenue Next 3Y-25.99%
Revenue Next 5Y184.95%
EBIT growth 1Y31.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.93%
EBIT Next 3Y14.26%
EBIT Next 5Y-60.17%
FCF growth 1Y10.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.72%
OCF growth 3YN/A
OCF growth 5YN/A